Baxter International Inc. Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Baxter International Inc. is a large accelerated filer operating in the healthcare sector. In Q2 2026, the company implemented a new operating model, consolidating its reportable segments from three to two: Medical Products & Therapies and Healthcare Systems & Technologies. The former Pharmaceuticals segment is now reported within Medical Products & Therapies. The company continues to manage the aftermath of its Kidney Care business sale (completed Jan 2025), which is reported as discontinued operations.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in millions) |
|---|---|
| Net Sales | $5,661 |
| Gross Margin | $1,923 (34.0% of sales) |
| Operating Income | $283 |
| Net Income (Attributable to Baxter) | $111 |
| Diluted EPS | $0.21 |
| Operating Cash Flow (Continuing Ops) | $510 |
| Cash and Cash Equivalents | $2,150 |
| Total Debt (Current + Long-term) | $9,459 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4% year-over-year (YoY) to $5.66 billion for the six months ended June 30, 2026, compared to $5.44 billion in 2025. Organic sales growth was 2%.
- Profitability: Net income attributable to Baxter stockholders decreased significantly to $111 million from $217 million in the prior year period. This decline is largely attributed to the absence of the gain on the sale of the Kidney Care business in the prior year and higher special items.
- Segment Performance:
- Medical Products & Therapies: Sales up 5% YoY; Operating income down to $750 million from $847 million due to increased manufacturing costs and pricing reductions.
- Healthcare Systems & Technologies: Sales up 2% YoY; Operating income down to $262 million from $278 million.
- Special Items: Special items adversely impacted net income by $360 million ($0.70 per diluted share) for the six months ended June 30, 2026. Key drivers included business optimization charges ($75 million), separation-related costs ($33 million), and business transformation costs ($34 million).
- Tax Rate: The effective income tax rate was 22% for the six months ended June 30, 2026, compared to a benefit rate of (43)% in the prior year, which included a significant tax benefit from an entity classification election.
Guidance, Outlook, Risks, and Unusual Items
- Novum LVP Recall: The company continues to face a Class I recall on its Novum IQ Large Volume Pump. Distribution and installation in the U.S. and Canada remain halted except for medical necessity. The company expects no meaningful sales from this product while the hold is in effect.
- Tariffs and Refunds: In Q2 2026, Baxter recorded approximately $75 million in tariff refunds (IEEPA) to cost of goods sold. However, the company expects continued adverse impacts from Section 122 duties and Section 301 tariffs.
- Legal and Regulatory:
- DOJ Investigations: The company is cooperating with DOJ investigations regarding Hillrom's respiratory health business and Baxter's IV flexible containers.
- Class Actions: Multiple class action lawsuits and derivative complaints have been filed alleging securities law violations and breaches of fiduciary duty related to the Novum LVP recall.
- Environmental: The company remains a potentially responsible party for Superfund sites, with reserves of $25 million.
- Capital Allocation: The quarterly dividend was reduced to $0.01 per share. No share repurchases were made in the first six months of 2026, with $1.30 billion remaining under the authorization.
- Credit Ratings: Standard & Poor's and Moody's revised the company's outlook from Stable to Negative in Q1 2026.
Investor Verification Checklist
- Novum LVP Resolution: Verify the timeline for regulatory clearance and the potential duration of the sales hold on the Novum LVP.
- Special Items Sustainability: Assess the run-rate of "business optimization" and "transformation" costs to determine if they are one-time or recurring.
- Tariff Exposure: Confirm the net impact of ongoing Section 122 and Section 301 tariffs versus the $75 million refund already recognized.
- Legal Reserves: Monitor the adequacy of reserves for the DOJ investigations and class action lawsuits related to Novum LVP.
- Dividend Policy: Evaluate the rationale behind the dividend reduction to $0.01 and the likelihood of future increases given the negative credit outlook.
- Goodwill Impairment Risk: Review the performance of the Front Line Care reporting unit ($1.51 billion goodwill) and Welch Allyn trade name ($390 million) for potential future impairments.